Lipoprotein(a) and Oxidized Phospholipids Independent Risk Factors for Cardiovascular Disease

Written By : Dr. Mahalakshmi Sivashankaran |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2023-05-11T20:00:33+05:30 | Updated On 12 May 2023 2:06 PM IST

USA: A new study published in the Journal of the American College of Cardiology has found that lipoprotein(a) (Lp[a]) and oxidized phospholipids (OxPLs) are independent risk factors for atherosclerotic cardiovascular disease.

The study aimed to evaluate the relationships between Lp(a) particle concentration and OxPLs associated with apolipoprotein B (OxPL-apoB) or apolipoprotein(a) (OxPL-apo[a]) with angiographic CAD and cardiovascular outcomes.

The study, which included 1,098 participants referred for coronary angiography, found that Lp(a) and OxPL-apoB were associated with multivessel CAD, with odds of multivessel CAD per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) being 1.10, 1.18, and 1.07, respectively.

Additionally, all biomarkers were associated with cardiovascular events, with hazard ratios for major adverse cardiovascular events per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) being 1.08, 1.15, and 1.07, respectively.

The study revealed the following key takeaways:

1. The median Lp(a) level among participants was 26.45 nmol/L.

2. Lp(a), OxPL-apoB, and OxPL-apo(a) were highly correlated.

3. Lp(a) and OxPL-apoB were associated with multivessel coronary artery disease (CAD).

4. The odds of having multivessel CAD doubled with increasing levels of Lp(a), OxPL-apoB, and OxPL-apo(a).

5. All three biomarkers were associated with cardiovascular events.

“The findings of the study suggest that Lp(a) and OxPL-apoB are important risk factors for atherosclerotic cardiovascular disease and should be considered when assessing risk in patients undergoing coronary angiography. The study also highlights the need for further research into the role of OxPLs in the development and progression of cardiovascular disease.” Said Dr. Thomas Gilliand, the lead author of the study.

Statins are commonly prescribed to reduce the risk of cardiovascular disease, the extent to which Lp(a) and OxPLs predict CAD severity and outcomes in a contemporary, statin-treated cohort is not well established, highlighting the need for further research in this area.

Reference:

Gilliand T., Liu Y., Mohebi R., Miksenas, Haidermota S., Wong M., et al.; Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes; J Am Coll Cardiol. 2023 May, 81 (18) 1780–1792; doi: 10.1016/j.jacc.2023.02.050

Lipoprotein(a)PhospholipidsOxidized Phospholipidscardiovascular risk.cardiovascular diseaseJournal of the American College of CardiologyJACCCAD

Article Source : Journal of the American College of Cardiology

Dr. Mahalakshmi Sivashankaran

Dr. Mahalakshmi Sivashankaran joined Medical Dialogues as an Intern in 2023. She is a BDS graduate from Manipal College of Dental Sciences, Mangalore Batch 2022, and worked as a Junior Resident at VMMC & Safdarjung Hospital at the Department of Dental Surgery till January 2023. She has completed a Diploma in Executive Healthcare management from the Loyola Institute of Business Administration, developing skills in Healthcare Management and Administration. She covers several medical specialties including Dental, ENT, Diagnostics, Pharmacology, Neurology, and Cardiology.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751